Table 1.

Sapitinib sensitized both paclitaxel and doxorubicin to SW620/Ad300 and HEK293/ABCB1 cells.

Treatment	IC50 ± SDa (RFb) (μM)
	SW620	SW620/Ad300	HEK293/pcDNA3.1	HEK293/ABCB1
Paclitaxel  + Sapitinib (1 μM)  + Sapitinib (5 μM)  + Verapamil (5 μM)	0.028 ± 0.007 (1.00) 0.029 ± 0.003 (1.04) 0.024 ± 0.005 (0.86) 0.027 ± 0.007 (0.96)	4.705 ± 0.089 (168.03)    0.359 ± 0.066 (12.82)*  0.029 ± 0.005 (1.04)*  0.022 ± 0.004 (0.79)*	0.075 ± 0.006 (1.00) 0.065 ± 0.050 (0.87) 0.063 ± 0.009 (0.84) 0.074 ± 0.017 (0.99)	2.024 ± 0.175 (26.99) 0.140 ± 0.108 (1.87)* 0.081 ± 0.021 (1.08)* 0.055 ± 0.014 (0.73)*
Doxorubicin  + Sapitinib (1 μM)  + Sapitinib (5 μM)  + Verapamil (5 μM)	0.055 ± 0.039 (1.00) 0.056 ± 0.022 (0.91) 0.044 ± 0.014 (0.79) 0.051 ± 0.022 (0.91)	6.013 ± 0.222 (109.32)  0.060 ± 0.018 (1.07)*  0.083 ± 0.031 (1.48)*  0.054 ± 0.048 (0.96)*	0.036 ± 0.011 (1.00) 0.030 ± 0.012 (0.83) 0.022 ± 0.007 (0.61) 0.038 ± 0.003 (1.06)	0.516 ± 0.038 (14.33) 0.037 ± 0.007 (1.03)* 0.021 ± 0.002 (0.58)* 0.034 ± 0.006 (0.94)*
Cisplatin  + Sapitinib (1 μM)  + Sapitinib (5 μM)  + Verapamil (5 μM)	1.036 ± 0.226 (1.00) 0.966 ± 0.157 (0.93) 1.004 ± 0.115 (0.97) 0.809 ± 0.350 (0.78)	1.391 ± 0.059 (1.34) 0.915 ± 0.100 (0.88) 1.085 ± 0.115 (1.05) 0.981 ± 0.120 (0.95)	1.293 ± 1.026 (1.00) 1.585 ± 1.030 (1.23) 1.477 ± 0.761 (1.14) 1.476 ± 1.015 (1.14)	1.333 ± 0.807 (1.03) 1.365 ± 0.725 (1.06) 1.287 ± 1.169 (0.99) 1.557 ± 1.099 (1.20)

^*P < 0.05 versus no inhibitor group.

^aCalculated by three independent experiments.

^bCalculated by dividing the IC₅₀ values of substrates in the presence or absence of sapitinib by the IC₅₀ values of parental cells without verapamil or sapitinib.